As a company our core belief is that no patient should go untreated simply because the disease they are fighting is so rare that only a few thousand, or even a few hundred, people suffer from the condition. We are dedicated to providing new therapies and new hope for patients with rare diseases. We work closely with our industry trade association, the Pharmaceutical Research and Manufacturers of America (PhRMA). This group represents the country's leading research-based pharmaceutical and biotechnology companies as they go about the business of developing and providing medicines that support longer, healthier lives for patients.

Gregg Lapointe, chief operating officer of Sigma-Tau Pharmaceuticals, Inc., was named to the board of directors of PhRMA in March of 2006 and is currently serving a two year term in this role.

"Joining the leadership team of PhRMA, our industry's trade association, is a personal honor for me and for Sigma-Tau Pharmaceuticals," says Lapointe. "As a company, Sigma-Tau Pharmaceuticals strives to provide novel medicines for unmet medical needs of patients with rare diseases, and our corporate mission coincides well with PhRMA's aims to provide innovative prescription medicines and treatments that are saving lives and giving patients new hope for a healthier future.”

As part of this mission, Sigma-Tau Pharmaceuticals encourages health care providers, patients and their family members/caretakers to visit PhRMA's Patient Assistance Program site, HelpingPatients.org, for information on finding applicable programs.

The above link will take you outside the Sigma-Tau Pharmaceuticals, Inc. Web site. Sigma-Tau Pharmaceuticals is not responsible for content posted on HelpingPatients.org.